S9070

SB 220025 三盐酸盐

≥98% (HPLC), solid

• 同義詞: 5-(2-Aminopyrimidin-4-yl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole trihydrochloride
• 經驗公式（希爾表示法）: C₁₈H₁₉FN₆ · 3HCl
• CAS號碼: 197446-75-6
• 分子量：: 447.76
• MDL號碼: MFCD08705333
• 分類程式碼代碼: 12352200
• PubChem物質ID: 24724623
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: solid
• 顏色: white
• 溶解度: H₂O: 22 mg/mL
• 起源: GlaxoSmithKline
• SMILES 字串: Cl[H].Cl[H].Cl[H].Nc1nccc(n1)-c2c(ncn2C3CCNCC3)-c4ccc(F)cc4
• InChI: 1S/C18H19FN6.3ClH/c19-13-3-1-12(2-4-13)16-17(15-7-10-22-18(20)24-15)25(11-23-16)14-5-8-21-9-6-14;;;/h1-4,7,10-11,14,21H,5-6,8-9H2,(H2,20,22,24);3*1H
• InChI 密鑰: IPFBHUGKKONHFR-UHFFFAOYSA-N

描述

應用

SB 220025 trihydrochloride may be used in p38-mediated cell signaling studies.

生化／生理作用

SB 220025 is a potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC₅₀ value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induced production of TNF at an ED₅₀ value of 7.5 mg/kg. At 30 mg/kg, SB 220025 reduced the expression of TNF and inhibited angiogenesis by ~40%. In a further study, the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease was tested in murine collagen-induced arthritis and SB 220025 was able to prevent the progression of established arthritis.

特點和優勢

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges